Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

toxicity

  • Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After <sup>90</sup>Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity
    You have access
    Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity
    Matthew M. Cousins, Theresa P. Devasia, Christopher M. Maurino, Justin Mikell, Matthew J. Schipper, Ravi K. Kaza, Theodore. S. Lawrence, Kyle C. Cuneo and Yuni K. Dewaraja
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 882-889; DOI: https://doi.org/10.2967/jnumed.121.262447
  • You have access
    Management of Patients with Renal Failure Undergoing Dialysis During 131I Therapy for Thyroid Cancer
    Maximilien Vermandel, Pauline Debruyne, Amandine Beron, Laura Devos, Antoine Talbot, Jean-François Legrand, François Provôt and Georges Lion
    Journal of Nuclear Medicine August 1, 2020, 61 (8) 1161-1170; DOI: https://doi.org/10.2967/jnumed.119.232017
  • You have access
    Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Hendrik Bergsma, Kirsten van Lom, Marc H.G.P. Raaijmakers, M. Konijnenberg, B.L. Boen L.R. Kam, Jaap J.M. Teunissen, Wouter W. de Herder, Eric P. Krenning and Dik J. Kwekkeboom
    Journal of Nuclear Medicine March 1, 2018, 59 (3) 452-458; DOI: https://doi.org/10.2967/jnumed.117.189712
  • You have access
    Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors
    Maria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, Rebecca Dumont, Nicolas Marincek, Attila Kollar, Philippe Brunner, Jan Beyersmann, Jan Müller-Brand, Helmut R. Maecke, Markus Laimer and Martin A. Walter
    Journal of Nuclear Medicine January 1, 2017, 58 (1) 97-102; DOI: https://doi.org/10.2967/jnumed.116.180687
  • You have access
    Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
    Stephen A. Deppen, Eric Liu, Jeffrey D. Blume, Jeffrey Clanton, Chanjuan Shi, Laurie B. Jones-Jackson, Vipul Lakhani, Richard P. Baum, Jordan Berlin, Gary T. Smith, Michael Graham, Martin P. Sandler, Dominique Delbeke and Ronald C. Walker
    Journal of Nuclear Medicine May 1, 2016, 57 (5) 708-714; DOI: https://doi.org/10.2967/jnumed.115.163865
  • You have access
    Safety of Repeated Radioembolizations in Patients with Advanced Primary and Secondary Liver Tumors and Progressive Disease After First Selective Internal Radiotherapy
    Alina Zarva, Konrad Mohnike, Robert Damm, Juri Ruf, Ricarda Seidensticker, Gerhard Ulrich, Max Seidensticker, Maciej Pech, Jens Ricke and Holger Amthauer
    Journal of Nuclear Medicine March 1, 2014, 55 (3) 360-366; DOI: https://doi.org/10.2967/jnumed.113.127662
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire